Evidence map›Paper›PMID 40782789›Full record

ArticleMolecular therapy : the journal of the American Society of Gene Therapy2025

Cancer interrupted: A story of oncolytic HSV-induced killing.

Upasana Sahu, Balveen Kaur

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Molecular therapy : the journal of the American Society of Gene Therapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Upasana SahuDepartment of Pathology, Medical College of Georgia at Augusta University, Augusta, GA, USA; Georgia Cancer Center at Augusta University, Augusta, GA, USA.
Balveen KaurDepartment of Pathology, Medical College of Georgia at Augusta University, Augusta, GA, USA; Georgia Cancer Center at Augusta University, Augusta, GA, USA. Electronic address: bkaur@augusta.edu.

Funding

The Tumor Microenvironmental Barrier to Effective Viral OncolysisP01CA163205 · NCI · OHIO STATE UNIVERSITY · PI MICHAEL A CALIGIURI · 2013 to 2026
$26.0M
Next Gen Virotherapy for GBMR01NS127473 · NINDS · UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON · PI Balveen Kaur · 2022 to 2026
$2.6M
Next generation oncolytic virotherapy targeting AKT and ERK signaling in gliomaR01NS137577 · NINDS · LSU HEALTH SCIENCES CENTER · PI Balveen Kaur · 2024 to 2026
$1.7M
Optimizing oncolytic virus therapy for glioblastomaR61NS112410 · NINDS · UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON · PI KAUR, BALVEEN · 2019 to 2020
$775k
NCI NIH HHS P01 CA163205NINDS NIH HHS R01 NS127473NINDS NIH HHS R01 NS137577NINDS NIH HHS R61 NS112410
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Identifiers

PMID40782789
PMCPMC12432878

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.